Identification

Name
Eprosartan
Accession Number
DB00876  (APRD00950)
Type
Small Molecule
Groups
Approved
Description

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

Structure
Thumb
Synonyms
  • (e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
  • (e)-3-[2-N-Butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
  • (e)-Alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
  • Éprosartan
  • Eprosartan
  • Eprosartanum
External IDs
SK&F-108566 / SKF 108566
Product Ingredients
IngredientUNIICASInChI Key
Eprosartan mesylate8N2L1NX8S3144143-96-4DJSLTDBPKHORNY-XMMWENQYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TevetenTablet400 mg/1OralAbbvie2010-05-242016-04-05Us
TevetenTablet400 mgOralBgp Pharma Ulc2000-09-08Not applicableCanada
TevetenTablet600 mg/1OralAbbvie2010-05-242016-04-05Us00074 3040 11 nlmimage10 db1d6dfb
TevetenTablet600 mgOralBgp Pharma Ulc2001-05-25Not applicableCanada
Teveten Tablets 300 mgTablet300 mgOralSolvay Pharma Inc2000-09-082003-01-02Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eprosartan MesylateTablet, film coated600 mg/1OralMylan Pharmaceuticals2011-12-20Not applicableUs
International/Other Brands
Eprozar (INTAS Pharmaceuticals) / Futuran (Merck)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAbbvie2010-05-242016-04-05Us
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralAbbvie2010-05-242016-04-22Us00074 3020 11 nlmimage10 e01d703b
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2005-05-06Not applicableUs
Teveten PlusEprosartan (600 mg) + Hydrochlorothiazide (12.5 mg)TabletOralBgp Pharma Ulc2004-07-06Not applicableCanada
Categories
UNII
2KH13Z0S0Y
CAS number
133040-01-4
Weight
Average: 424.513
Monoisotopic: 424.145677956
Chemical Formula
C23H24N2O4S
InChI Key
OROAFUQRIXKEMV-LDADJPATSA-N
InChI
InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
IUPAC Name
4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
SMILES
CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O

Pharmacology

Indication

For the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).

Structured Indications
Pharmacodynamics

Angiotensin II, the principal pressor agent of the renin-angiotensin system, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]. It is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Eprosartan selectively blocks the binding of angiotensin II to the AT1 receptor, which in turn leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.

Mechanism of action

Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Eprosartan does not exhibit any partial agonist activity at the AT1 receptor. Its affinity for the AT1 receptor is 1,000 times greater than for the AT2 receptor. In vitro binding studies indicate that eprosartan is a reversible, competitive inhibitor of the AT1 receptor. Eprosartan has also been shown to bind to AT1 receptors both presynaptically and synaptically. Its action on presynaptic AT1 receptors results in the inhibition of sympathetically stimulated noradrenaline release. Unlike ACE inhibitors, eprosartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Absolute bioavailability following a single 300 mg oral dose of eprosartan is approximately 13%. Administering eprosartan with food delays absorption.

Volume of distribution
Not Available
Protein binding

Plasma protein binding of eprosartan is high (approximately 98%) and constant over the concentration range achieved with therapeutic doses.

Metabolism

Eprosartan is not metabolized by the cytochrome P450 system. It is mainly eliminated as unchanged drug. Less than 2% of an oral dose is excreted in the urine as a glucuronide.

Route of elimination
Not Available
Half life

The terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.

Clearance
Not Available
Toxicity

There was no mortality in rats and mice receiving oral doses of up to 3000 mg eprosartan/kg and in dogs receiving oral doses of up to 1000 mg eprosartan/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Eprosartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Eprosartan.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acemetacin.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Eprosartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Alminoprofen.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Eprosartan.Approved, Withdrawn
AmbrisentanEprosartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineEprosartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Eprosartan.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Eprosartan.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eprosartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Eprosartan.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Eprosartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Eprosartan.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Eprosartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Eprosartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Eprosartan.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eprosartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Eprosartan.Approved
AvanafilAvanafil may increase the antihypertensive activities of Eprosartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Eprosartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Eprosartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Eprosartan.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Eprosartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Eprosartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benzydamine.Approved
BepridilEprosartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Eprosartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Eprosartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Eprosartan.Experimental
BimatoprostEprosartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eprosartan.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Eprosartan.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Eprosartan.Approved, Investigational
BQ-123Eprosartan may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Eprosartan.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Eprosartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Eprosartan.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Eprosartan.Approved, Investigational
BupranololEprosartan may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Eprosartan.Experimental
CafedrineEprosartan may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Eprosartan.Approved
CandesartanEprosartan may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Eprosartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Eprosartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Eprosartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Eprosartan.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Celecoxib.Approved, Investigational
CeliprololEprosartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Eprosartan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Eprosartan.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Choline magnesium trisalicylate.Approved
CicletanineEprosartan may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Eprosartan.Approved, Investigational
CiprofloxacinEprosartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Eprosartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Eprosartan.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Eprosartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clonixin.Approved
CloranololEprosartan may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Eprosartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Eprosartan.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Eprosartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Eprosartan is combined with Curcumin.Investigational
CyclopenthiazideEprosartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineEprosartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Eprosartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Eprosartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Eprosartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Eprosartan.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Eprosartan.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Delapril.Experimental
DeserpidineEprosartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Eprosartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eprosartan.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Eprosartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenamide.Approved
diethylnorspermineEprosartan may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Eprosartan.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Eprosartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Eprosartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eprosartan.Approved
DrospirenoneEprosartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Droxicam.Approved
DuloxetineEprosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Eprosartan is combined with E-6201.Investigational
EfonidipineEprosartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Eprosartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Eprosartan.Approved
EpanololEprosartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Eprosartan.Approved
EpoprostenolEprosartan may increase the hypotensive activities of Epoprostenol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Eprosartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Eprosartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Eprosartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Feprazone.Experimental
Ferulic acidEprosartan may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Eprosartan.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Eprosartan.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Eprosartan.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Eprosartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Eprosartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Eprosartan.Approved
GuanazodineEprosartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineEprosartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Guanfacine.Approved, Investigational
GuanoclorEprosartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzEprosartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanEprosartan may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Eprosartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Eprosartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
HexamethoniumEprosartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Eprosartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Eprosartan.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Eprosartan.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Eprosartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Eprosartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Eprosartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Eprosartan.Approved
IndenololEprosartan may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Eprosartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Eprosartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Eprosartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Eprosartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Eprosartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Eprosartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Eprosartan.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Eprosartan.Approved
LacidipineEprosartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Eprosartan.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Eprosartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Eprosartan.Approved, Investigational
LevodopaEprosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Eprosartan.Approved, Investigational
LinsidomineEprosartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Eprosartan.Approved
LofexidineEprosartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Eprosartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lumiracoxib.Approved, Investigational
MacitentanEprosartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate.Approved
ManidipineEprosartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Eprosartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eprosartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole.Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Eprosartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Eprosartan.Approved
MethoserpidineEprosartan may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Eprosartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Eprosartan.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Eprosartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Eprosartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Eprosartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eprosartan.Approved, Investigational
MetyrosineEprosartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilEprosartan may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Eprosartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Eprosartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Eprosartan.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Eprosartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Eprosartan.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Eprosartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Eprosartan.Approved, Investigational
MuzolimineEprosartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Eprosartan.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Eprosartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naftifine.Approved
NaftopidilEprosartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Eprosartan.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eprosartan.Approved
NicorandilNicorandil may increase the hypotensive activities of Eprosartan.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Niflumic Acid.Approved
NiguldipineEprosartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineEprosartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Eprosartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eprosartan.Approved
NitrendipineEprosartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Eprosartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Eprosartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eprosartan.Approved
ObinutuzumabEprosartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Eprosartan.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Eprosartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.Approved
OxprenololEprosartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eprosartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Eprosartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
PentoliniumEprosartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Eprosartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Eprosartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Eprosartan.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Eprosartan.Approved
PhenoxybenzamineEprosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Eprosartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Eprosartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Eprosartan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eprosartan.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Eprosartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Eprosartan.Withdrawn
Platelet Activating FactorEprosartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideEprosartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Eprosartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Eprosartan.Approved
PrimidonePrimidone may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Eprosartan.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Eprosartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Eprosartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Eprosartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Eprosartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Eprosartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eprosartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Eprosartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Eprosartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Eprosartan.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Riociguat.Approved
RisperidoneEprosartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEprosartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Eprosartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Eprosartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Eprosartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Eprosartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Eprosartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salsalate.Approved
SaprisartanEprosartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Eprosartan.Approved, Investigational, Vet Approved
SelexipagEprosartan may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Eprosartan is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Eprosartan is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Eprosartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Eprosartan.Approved, Investigational
SitaxentanEprosartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Eprosartan.Approved
Sodium phosphateEprosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Eprosartan.Approved
SRT501The risk or severity of adverse effects can be increased when Eprosartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Eprosartan.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eprosartan.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Eprosartan.Approved, Investigational
TalinololEprosartan may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Eprosartan.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Teriflunomide.Approved
TerlipressinEprosartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineEprosartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Eprosartan.Approved, Investigational, Withdrawn
TheodrenalineEprosartan may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Eprosartan.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tiaprofenic acid.Approved
TiboloneEprosartan may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenEprosartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Eprosartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Eprosartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Eprosartan.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin.Approved
TolonidineEprosartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Eprosartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Eprosartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Eprosartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Eprosartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Eprosartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Eprosartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Eprosartan.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Eprosartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Eprosartan.Approved
TribenosideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tribenoside.Experimental
TrichlormethiazideEprosartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Eprosartan.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Eprosartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Eprosartan.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Eprosartan.Approved, Investigational
UnoprostoneEprosartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Eprosartan.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Eprosartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Eprosartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.Approved
VincamineEprosartan may increase the hypotensive activities of Vincamine.Experimental
VinpocetineEprosartan may increase the hypotensive activities of Vinpocetine.Investigational
XipamideEprosartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineEprosartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Eprosartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zomepirac.Withdrawn
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Richard T. Matsuoka, Peng Liu, "Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates." U.S. Patent US6294675, issued June, 1992.

US6294675
General References
  1. Ruilope L, Jager B, Prichard B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001;10(4):223-9. [PubMed:11800061]
  2. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062]
  3. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389]
  4. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247]
  5. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407]
  6. Blankestijn PJ, Rupp H: Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. [PubMed:18855637]
External Links
Human Metabolome Database
HMDB15014
KEGG Drug
D04040
KEGG Compound
C07467
PubChem Compound
5281037
PubChem Substance
46506765
ChemSpider
4444504
BindingDB
50011977
ChEBI
4814
ChEMBL
CHEMBL813
Therapeutic Targets Database
DAP001367
PharmGKB
PA449481
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Eprosartan
ATC Codes
C09CA02 — EprosartanC09DA02 — Eprosartan and diuretics
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
FDA label
Download (1.09 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableKidney Diseases1
3CompletedTreatmentHypertension,Essential1
4CompletedNot AvailableHealthy Volunteers1
4CompletedNot AvailableHypertension,Essential1
Not AvailableCompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral600 mg/1
TabletOral400 mg/1
TabletOral400 mg
TabletOral600 mg
TabletOral600 mg/1
TabletOral
TabletOral300 mg
Prices
Unit descriptionCostUnit
Teveten hct 600-12.5 mg tablet3.52USD tablet
Teveten hct 600-25 mg tablet3.42USD tablet
Teveten 600 mg tablet3.19USD tablet
Teveten 400 mg tablet2.83USD tablet
Teveten 400 mg tiltab1.24USD tablet
Teveten 600 mg Tablet1.18USD tablet
Teveten 400 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5656650No1994-08-122014-08-12Us
US5185351No1993-02-092010-02-09Us
CA2250395No2005-09-062017-03-26Canada
CA2115170No2004-05-252012-08-12Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)248-250 °C (mesylate form)Not Available
water solubilityInsoluble (mesylate form)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00866 mg/mLALOGPS
logP3.57ALOGPS
logP3.8ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.63ChemAxon
pKa (Strongest Basic)6.93ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.42 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.02 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9863
Blood Brain Barrier-0.6931
Caco-2 permeable-0.6261
P-glycoprotein substrateSubstrate0.8011
P-glycoprotein inhibitor INon-inhibitor0.8577
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.7673
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.5798
CYP450 2C9 inhibitorNon-inhibitor0.6617
CYP450 2D6 inhibitorNon-inhibitor0.8325
CYP450 2C19 inhibitorNon-inhibitor0.6234
CYP450 3A4 inhibitorNon-inhibitor0.6086
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.644
Ames testNon AMES toxic0.7313
CarcinogenicityNon-carcinogens0.9454
BiodegradationNot ready biodegradable0.6117
Rat acute toxicity2.4288 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9464
hERG inhibition (predictor II)Non-inhibitor0.8827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0009000000-fa421ee23b907968b800
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-694c481f9555295f9426
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004u-0289000000-647b9ea41a7a812dea66
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00kg-0290000000-08e189bdaeb9c6af3b4f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014j-1290000000-e8207e65f017389d706f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00lr-9260000000-7b844b75045cf89e145e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-9100000000-f49fc8384f38dc7b6e3b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-e62e6d74d830487d0954
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002u-0198000000-d571b7bcdbe9e3f7e69f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00kp-0290000000-0b7c3fe664812ce51596
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014j-1090000000-85f4ee357273ee0268c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-9240000000-8ed6c4fadafd173a2579
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-9400000000-81bd0b20c45458b1bdec
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0009000000-0333ac2f95788dceda2c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-0196300000-c2476723863e5584d7e8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0000900000-a93af7ff9cf5786971d0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-056r-0171900000-4a8d34412967af4cbf35
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1971000000-ee85641cdce897ab6693
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1920000000-282ecc38e7c0c6cbefef
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1900000000-1a109162fa90e4ce7932
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-2900000000-54946c90c1dfdf5eb21e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0000900000-f33c4c2419ad566fa726
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-056r-1172900000-e0852717bfa6c5f8f0cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1970000000-fed4d418faa53031f6ca
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1920000000-2ddeec1f39e95c27109d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4r-1910000000-2953fc7d89567648d5ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1900000000-1e52f8edbad114f026d5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-0196300000-e398b1a8add5df82164b

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acids
Alternative Parents
Imidazolyl carboxylic acids and derivatives / Benzoyl derivatives / 1,2,5-trisubstituted imidazoles / N-substituted imidazoles / Dicarboxylic acids and derivatives / Thiophenes / Heteroaromatic compounds / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Benzoic acid / 1,2,5-trisubstituted-imidazole / Benzoyl / Imidazolyl carboxylic acid derivative / Trisubstituted imidazole / Dicarboxylic acid or derivatives / N-substituted imidazole / Azole / Heteroaromatic compound / Imidazole
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, thiophenes, dicarboxylic acid (CHEBI:4814)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Heusser K, Vitkovsky J, Schmieder RE, Schobel HP: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci. 2003 Aug 29;107(1):45-51. [PubMed:12927226]
  3. Gremmler B, Kunert M, Schleiting H, Ulbricht LJ: Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Fail. 2000 Jun;2(2):183-7. [PubMed:10856732]
  4. Suzuki G, Mishima T, Tanhehco EJ, Sharov VG, Todor A, Rostogi S, Gupta RC, Chaudhry PA, Anagnostopoulos PV, Nass O, Goldstein S, Sabbah HN: Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol. 2003 Jan;138(2):301-9. [PubMed:12540520]
  5. Ilson BE, Martin DE, Boike SC, Jorkasky DK: The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol. 1998 May;38(5):437-41. [PubMed:9602957]
  6. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA: Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan. Eur J Pharmacol. 2003 May 23;469(1-3):117-24. [PubMed:12782193]
  7. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062]
  8. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389]
  9. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247]
  10. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407]
  11. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ: ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001 May;141(5):800-7. [PubMed:11320369]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34